PL3691692T3 - Anti-cd71 activatable antibody drug conjugates and methods of use thereof - Google Patents

Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Info

Publication number: PL3691692T3
Authority: PL; Poland
Prior art keywords: methods; drug conjugates; antibody drug; activatable antibody; activatable
Prior art date: 2017-10-14

Application number

PL18797311T

Other languages

Polish (pl)

Inventor

Shweta SINGH

Jennifer Hope RICHARDSON

Laura Patterson SERWER

Jonathan Alexander Terrett

Susan E. Morgan-Lappe

Tracy HENRIQUES

Sherry L. RALSTON

Marvin Robert Leanna

Ilaria BADAGNANI

Sahana Bose

Original Assignee

Abbvie Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-14

Filing date

2018-10-12

Publication date

2021-07-19

2018-10-12 Application filed by Abbvie Inc. filed Critical Abbvie Inc.

2021-07-19 Publication of PL3691692T3 publication Critical patent/PL3691692T3/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL18797311T 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof PL3691692T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762572467P	2017-10-14	2017-10-14
EP18797311.0A EP3691692B8 (en)	2017-10-14	2018-10-12	Anti-cd71 activatable antibody drug conjugates and methods of use thereof
PCT/US2018/055733 WO2019075417A1 (en)	2017-10-14	2018-10-12	Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3691692T3 true PL3691692T3 (en)	2021-07-19

Family

ID=64110112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18797311T PL3691692T3 (en)	2017-10-14	2018-10-12	Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Country Status (36)

Country	Link
US (3)	US20190111150A1 (en)
EP (2)	EP3834846A1 (en)
JP (2)	JP7374891B2 (en)
KR (4)	KR102529359B1 (en)
CN (1)	CN111278467B (en)
AR (1)	AR115178A1 (en)
AU (1)	AU2018346969A1 (en)
BR (1)	BR112020007302B1 (en)
CA (1)	CA3077730A1 (en)
CL (1)	CL2020000977A1 (en)
CO (1)	CO2020005685A2 (en)
CR (1)	CR20200206A (en)
CY (1)	CY1123968T1 (en)
DK (1)	DK3691692T3 (en)
DO (1)	DOP2023000150A (en)
EC (1)	ECSP20025198A (en)
ES (1)	ES2864013T3 (en)
HR (1)	HRP20210436T8 (en)
HU (1)	HUE054037T2 (en)
IL (1)	IL273586A (en)
LT (1)	LT3691692T (en)
MA (1)	MA50752B1 (en)
MD (1)	MD3691692T2 (en)
MX (1)	MX2020003723A (en)
PE (1)	PE20210125A1 (en)
PH (1)	PH12020550417A1 (en)
PL (1)	PL3691692T3 (en)
PT (1)	PT3691692T (en)
RS (1)	RS61596B1 (en)
RU (2)	RU2022111211A (en)
SG (1)	SG11202003378WA (en)
SI (1)	SI3691692T1 (en)
SM (1)	SMT202100184T1 (en)
TW (2)	TW202330039A (en)
UY (1)	UY37931A (en)
WO (1)	WO2019075417A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130116404A1 (en)	2011-11-08	2013-05-09	Case Western Reserve University	Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (en)	2015-05-04	2018-07-17	Cytomx Therapeutics Inc	anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of using these
DK3635009T3 (en)	2017-06-07	2026-03-30	Regeneron Pharma	Compositions and methods for internalizing enzymes
PL3691692T3 (en) *	2017-10-14	2021-07-19	Abbvie Inc.	Anti-cd71 activatable antibody drug conjugates and methods of use thereof
US12258597B2 (en)	2018-02-07	2025-03-25	Regeneron Pharmaceuticals, Inc.	Methods and compositions for therapeutic protein delivery
WO2019183633A1 (en)	2018-03-23	2019-09-26	Case Western Reserve Univeristy	Psma targeted conjugate compounds and uses thereof
BR112020023145A2 (en)	2018-05-17	2021-02-02	Regeneron Pharmaceuticals, Inc.	anti-cd63 antibody or antigen-binding fragment thereof, bispecific antigen-binding molecule, therapeutic protein of multiple domains, polynucleotide pharmaceutical composition, and, compound
CN121754667A (en) *	2020-04-08	2026-03-31	阿里亚达治疗公司	Compositions and methods for blood brain barrier delivery
JP2023521384A (en) *	2020-04-09	2023-05-24	シートムエックスセラピューティクス，インコーポレイテッド	Compositions containing activatable antibodies
CN116194470B (en) *	2020-07-23	2025-10-03	达因疗法公司	Muscle targeting complexes and uses thereof
US20250332265A1 (en)	2021-11-09	2025-10-30	Case Western Reserve University	Psma targeted conjugate compounds and uses thereof
CN120659627A (en) *	2022-07-29	2025-09-16	瑞泽恩制药公司	Compositions and methods for transferrin receptor (TFR) -mediated brain and muscle delivery
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) *	2023-12-20	2025-06-26	Institut National De La Sante Et De La Recherche Medicale	Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0279862B1 (en)	1986-08-28	1993-11-03	Teijin Limited	Cytocidal antibody complex and process for its preparation
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
DK0752248T3 (en)	1992-11-13	2000-11-13	Idec Pharma Corp	Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antibody
AU2006284651C1 (en)	2005-08-31	2013-09-12	The Regents Of The University Of California	Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
CN101888856B (en) *	2007-11-07	2014-08-27	塞尔德克斯医疗公司	Antibody that binds to human dendritic and epithelial cells 205 (DEC-205)
RU2636046C2 (en)	2009-01-12	2017-11-17	Сайтомкс Терапьютикс, Инк	Modified antibodies composition, methods of production and application
AU2010241706B2 (en) *	2009-04-29	2015-07-09	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	ERG monoclonal antibodies
CA2761310C (en)	2009-05-07	2017-02-28	Charles S. Craik	Antibodies and methods of use thereof
WO2012104344A1 (en) *	2011-02-01	2012-08-09	Genmab A/S	Human antibodies and antibody-drug conjugates against cd74
PL2809683T3 (en) *	2012-01-31	2019-03-29	Sbi Biotech Co., Ltd.	Anti-phospholipase d4 antibody
EP2882844B1 (en)	2012-08-10	2018-10-03	Cytomx Therapeutics Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (en) *	2013-02-05	2014-05-21	浙江大学	Anti-CD20 antibody-monomethyl auristatin E conjugate, preparation method and application thereof
BR112017023862A2 (en) *	2015-05-04	2018-07-17	Cytomx Therapeutics Inc	anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of using these
CN106237341B (en) *	2016-07-12	2019-07-30	浙江大学	A kind of antibody conjugated drug and its preparation method and application
PL3691692T3 (en) *	2017-10-14	2021-07-19	Abbvie Inc.	Anti-cd71 activatable antibody drug conjugates and methods of use thereof

2018
- 2018-10-12 PL PL18797311T patent/PL3691692T3/en unknown
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/en active Active
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/en unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/en unknown
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en not_active Withdrawn
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/en not_active Ceased
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en not_active Abandoned
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/en unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/en active Active
- 2018-10-12 TW TW107136020A patent/TWI780237B/en not_active IP Right Cessation
- 2018-10-12 AR ARP180102966A patent/AR115178A1/en not_active Application Discontinuation
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/en active Active
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/en not_active Withdrawn
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/en unknown
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 SI SI201830233T patent/SI3691692T1/en unknown
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/en unknown
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/en active
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/en active Active
- 2018-10-12 RS RS20210341A patent/RS61596B1/en unknown
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/en active IP Right Grant
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/en unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/en unknown
- 2018-10-12 MA MA50752A patent/MA50752B1/en unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/en unknown
- 2018-10-12 PT PT187973110T patent/PT3691692T/en unknown
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en not_active Ceased
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/en not_active Expired - Fee Related
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/en unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/en not_active Application Discontinuation
- 2018-10-12 CR CR20200206A patent/CR20200206A/en unknown
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/en active
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/en unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/en unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/en unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/en unknown
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/en unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/en active Pending

Also Published As

Publication number	Publication date
RU2771292C2 (en)	2022-04-29
RU2020115713A (en)	2021-11-16
CR20200206A (en)	2021-02-18
RU2022111211A (en)	2022-05-05
PH12020550417A1 (en)	2021-04-12
MA50752B1 (en)	2021-03-31
DOP2023000150A (en)	2023-08-31
HRP20210436T8 (en)	2022-01-07
SMT202100184T1 (en)	2021-05-07
HUE054037T2 (en)	2021-08-30
RU2020115713A3 (en)	2022-02-25
AR115178A1 (en)	2020-12-09
MX2020003723A (en)	2020-07-22
US20190111150A1 (en)	2019-04-18
KR20230004932A (en)	2023-01-06
EP3691692B1 (en)	2020-12-30
WO2019075417A1 (en)	2019-04-18
AU2018346969A1 (en)	2020-04-23
CN111278467B (en)	2024-07-30
SI3691692T1 (en)	2021-04-30
KR20220045088A (en)	2022-04-12
RS61596B1 (en)	2021-04-29
JP2020537649A (en)	2020-12-24
CY1123968T1 (en)	2022-05-27
JP2024012366A (en)	2024-01-30
TWI780237B (en)	2022-10-11
CA3077730A1 (en)	2019-04-18
PT3691692T (en)	2021-03-29
CN111278467A (en)	2020-06-12
KR102529359B1 (en)	2023-05-09
BR112020007302B1 (en)	2023-01-31
SG11202003378WA (en)	2020-05-28
LT3691692T (en)	2021-05-10
PE20210125A1 (en)	2021-01-19
MD3691692T2 (en)	2021-05-31
HRP20210436T1 (en)	2021-04-30
DK3691692T3 (en)	2021-03-22
TW202330039A (en)	2023-08-01
JP7374891B2 (en)	2023-11-07
IL273586A (en)	2020-05-31
BR112020007302A2 (en)	2020-09-29
KR102385495B1 (en)	2022-04-15
CO2020005685A2 (en)	2020-05-15
TW201927815A (en)	2019-07-16
KR20230070046A (en)	2023-05-19
EP3691692B8 (en)	2021-05-26
EP3691692A1 (en)	2020-08-12
US20240115724A1 (en)	2024-04-11
US20210145978A1 (en)	2021-05-20
KR20200070324A (en)	2020-06-17
ES2864013T3 (en)	2021-10-13
ECSP20025198A (en)	2020-06-30
CL2020000977A1 (en)	2020-09-11
UY37931A (en)	2019-04-30
EP3834846A1 (en)	2021-06-16
MA50752A (en)	2020-08-12

Publication	Publication Date	Title
IL273586A (en)	2020-05-31	Anti-cd71 activatable antibody drug conjugates and methods of use thereof
IL272703A (en)	2020-04-30	Activatable anti-cd166 antibodies and methods of use thereof
IL270921A (en)	2020-01-30	Activatable anti-pdl1 antibodies, and methods of use thereof
IL304717A (en)	2023-09-01	Anti-cmet antibody drug conjugates and methods their use
ZA201801401B (en)	2019-08-28	Anti-dll3 antibody drug conjugates and methods of use
ZA201900059B (en)	2022-11-30	Anti-b7-h3 antibodies and antibody drug conjugates
IL282856A (en)	2021-06-30	Activatable anti-cd166 antibodies and methods of use thereof
ZA201801957B (en)	2020-07-29	Pyrrolobenzodiazepine antibody drug conjugates and methods of use
IL265625A (en)	2019-05-30	Activatable anti-ctla-4 antibodies and uses thereof
EP3572428A4 (en)	2020-12-30	ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE
IL261493A (en)	2018-11-29	Napi2b-targeted antibody-drug conjugates and methods of use thereof
SG10201913762QA (en)	2020-03-30	Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
EP3625253A4 (en)	2021-03-24	Activatable antibodies and methods of use thereof
EP3294810A4 (en)	2019-01-02	Silicon based drug conjugates and methods of using same
IL278225A (en)	2020-11-30	Anti-sez6 antibody drug conjugates and methods of use
IL272920A (en)	2020-04-30	Anti-egfr antibody drug conjugates (adc) and uses thereof
IL273048A (en)	2020-04-30	Melanin antibodies and uses thereof
HK40033435A (en)	2021-04-09	Activatable anti-cd166 antibodies and methods of use thereof
HK40004553A (en)	2020-04-29	Napi2b-targeted antibody-drug conjugates and methods of use thereof